Using a virus to treat lymphoma
Official title: Intravenous VSV virotherapy in lymphoma
Funded at Mayo Clinic Rochester · NIH-11083746 · Data updated 2026-11-12
This study is testing a new virus treatment for people with relapsed T cell lymphoma to see if it can safely target and kill cancer cells while sparing healthy ones, and it will also look at how well it works when combined with other immune therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | May 11, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $619,753 |
| NIH project number | 5R01CA262613-03 |
| Project ID | NIH-11083746 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with relapsed refractory T cell lymphoma who have not responded to previous treatments.
✕Less likely to help
Patients with early-stage lymphoma or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates a new treatment for relapsed refractory T cell lymphoma using an engineered virus called VSV-IFNβ-NIS. The virus is designed to selectively target and destroy cancer cells while leaving healthy cells unharmed. Patients will receive a single intravenous infusion of the virus, and the study aims to enhance treatment effectiveness by combining it with immune checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 antibodies. The goal is to improve patient responses and the duration of those responses to the treatment.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with difficult-to-treat lymphoma.
How similar studies have gone: Previous studies have shown promising results with similar virotherapy approaches, indicating potential for success in this novel application.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Peng, Kah-Whye — Mayo Clinic Rochester
- Study coordinator: Peng, Kah-Whye
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.